Latest Treatments of Parkinson's Disease Stories
Surveyed Neurologists and PCPs Vary in Their Prescribing Patterns of Levodopa/Carbidopa and Dopamine Agonists, According to a New Report from Decision Resources WALTHAM, Mass., March 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that second-line patient share of MAO-B inhibitors has increased from 14.1 percent to 35.2 percent since last year's report.
LOS ANGELES, Feb.
SEATTLE, Jan. 6 /PRNewswire/ -- Omeros Corporation today announced that The Michael J.
Levodopa has long been proven to provide the greatest relief of all available medications in the treatment of Parkinson's disease.
Sun Pharmaceutical Industries, a specialty pharmaceutical company, has received the FDA approval for the company's abbreviated new drug application for generic Sinemet CR, an extended release version of carbidopa with levodopa.
DETROIT, Nov. 5 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. announced today, that it has launched Carbidopa and Levodopa tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma).
Neurogen's new dopamine agonist aplindore has shown positive results in Phase II trials in the treatment of Parkinson's disease and restless leg syndrome. Datamonitor estimates dopamine agonist sales in these indications were worth $1.5 billion in 2007.
Omeros and The Parkinson's Institute and Clinical Center have entered into a collaboration to evaluate a novel target, proprietary to Omeros, for the treatment of movement disorders.
AMSTERDAM, The Netherlands, September 18 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from Amgen to use their GDNF gene for the development of a gene therapy treatment for Parkinson's disease.
SEATTLE and SUNNYVALE, Calif., Sept. 17 /PRNewswire/ -- Omeros Corporation and The Parkinson's Institute and Clinical Center today announced that they have entered into a collaboration to evaluate a novel target, proprietary to Omeros, for the treatment of movement disorders.
- A serpent whose bite was fabled to produce intense thirst.